$ISRG

LOEB GARY sold $170K of ISRG

LOEB GARY (EVP & Chief Legal and Complian) sold 400 shares of INTUITIVE SURGICAL INC (ISRG) at $424.14 ($0.17M total) on 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LOEB GARY
Published Jun 10, 2026, 9:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 9:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ISRG
Neutral
medium confidence
Mentioned
$ISRG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

The disclosure adds a fresh datapoint on insider activity but does not include any operational, financial, or regulatory change.

02

Market read

A modest, pre-arranged insider sale is unlikely to drive a sustained repricing without accompanying company-specific catalysts.

03

What to watch

Traders may over-weight small insider sales; the key is whether there are repeated sales patterns or concurrent operational/regulatory news (not present here).

Relevance 3/10Novelty 8/10Timing: Filed 2026-06-10 (transaction dated 2026-06-10)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Intuitive Surgical (ISRG).

Company-level read

Ticker impact

$ISRGNeutralMedium confidence
Context

Intuitive Surgical disclosed an open-market sale by EVP & Chief Legal and Compliance Officer Gary Loeb: 400 shares sold at $424.14 on 2026-06-10 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and quickly absorbed.

Evidence & confidence

The filing is a Form 4 insider transaction and explicitly states a pre-arranged Rule 10b5-1 plan; the disclosed size ($169.7k) is small relative to typical ISRG market context, so it’s unlikely to change earnings or risk materially.

Market effects

No clear read-across to medical device sector fundamentals; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect liquidity/tax planning rather than bearish expectations.

Key entities

  • ISRG

    Intuitive Surgical, Inc., the subject of the Form 4 insider transaction.

  • Gary Loeb

    EVP & Chief Legal and Compliance Officer who sold 400 shares on 2026-06-10 under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ISRGHighAI 8/10

Intuitive receives CE mark for transvaginal use of da Vinci SP system

Intuitive Surgical (ISRG) received CE mark approval for its da Vinci SP system for transvaginal gynecological procedures in Europe, expanding its use in women's health. The system, already approved for other surgeries, allows single-incision operations, potentially improving recovery and outcomes. It is also approved in the US, Japan, and Korea.

$ISRGHigh

Intuitive announces expanded indication for da Vinci SP in Europe

Intuitive (ISRG) received CE mark approval for transvaginal gynecologic procedures using the da Vinci SP system in Europe, expanding its applications. The approval allows for less invasive options and potentially better recovery experiences. The system is already approved in the US, Japan, and Korea for various procedures.

$IARTMedAI 8/10

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Integra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.

$ISRGMed

ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now?

Intuitive Surgical (ISRG) trades at its lowest valuation in a decade, with a forward P/E of 30.26x, below its 10-year median. Despite a 40% decline, Q2 2026 revenue grew 19% to $2.89B, and EPS rose 28%. Management maintained 2026 da Vinci procedure growth forecast at 13.5-15.5%, citing international growth but noting U.S. and China uncertainties. ISRG's product pipeline includes da Vinci 5 and Ion systems, with innovations like SP procedures up 61%. Shares lag industry and sector, down 15% in 3